Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been given an average rating of “Hold” by the seven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $6.00.
A number of research analysts have recently commented on the company. Robert W. Baird downgraded Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Tuesday, July 30th. Zacks Investment Research upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 26th. ValuEngine downgraded Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pieris Pharmaceuticals in a research report on Friday, September 27th. Finally, William Blair restated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Friday, September 27th.
Shares of NASDAQ PIRS traded up $0.04 during midday trading on Thursday, reaching $3.25. 14,004 shares of the stock traded hands, compared to its average volume of 1,098,249. The stock has a market capitalization of $158.54 million, a PE ratio of -6.48 and a beta of 1.27. Pieris Pharmaceuticals has a one year low of $2.39 and a one year high of $6.04. The company’s 50 day moving average is $4.36 and its 200 day moving average is $4.18.
In related news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $4.50, for a total value of $225,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.59% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of Pieris Pharmaceuticals by 1,074.8% during the second quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 5,374 shares during the last quarter. Lindbrook Capital LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $37,000. Clear Harbor Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $47,000. Jane Street Group LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $47,000. Finally, BNP Paribas Arbitrage SA bought a new stake in shares of Pieris Pharmaceuticals during the first quarter worth $36,000. Institutional investors and hedge funds own 55.11% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Featured Article: How is the LIBOR rate calculated?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.